How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    Has all of the relevant evidence been taken into account?

  • Question on Consultation

    Are the summaries of clinical and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, sex, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic treatment

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about axicabtagene ciloleucel

Anticipated marketing authorisation indication

2.1 Axicabtagene ciloleucel (Yescarta, Kite) does not have a marketing authorisation in Great Britain yet. It received a marketing authorisation by the European Commission for: 'the treatment of adult patients with diffuse large B‑cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) that relapses within 12 months from completion of, or are refractory to, first-line chemoimmunotherapy'.

Dosage in the marketing authorisation

2.2 The dosage schedule will be available in the summary of product characteristics for axicabtagene ciloleucel.

Price

2.3 The list price of axicabtagene ciloleucel for a single infusion including shipping, engineering and generation of CAR T-cells is £280,451 (company submission).

2.4 The company has a commercial arrangement (simple discount patient access scheme). This makes axicabtagene ciloleucel available to the NHS with a discount and it would have also applied to this indication if the technology had been recommended. The size of the discount is commercial in confidence. It is the company's responsibility to let relevant NHS organisations know details of the discount.